Reven Pharmaceuticals
Reven is a biotechnology and pharmaceutical company focused on developing innovative drug therapies, particularly through its RJX platform technology. Established in 1999, Reven has a mission to pursue scientific innovation to improve health and well-being, with ongoing research, clinical trials, and collaborations aimed at addressing unmet medical needs across various therapeutic areas including autoimmune, metabolic, sepsis, inflammation, oncology, cardiovascular, CNS, ocular, and more. The company has a history of pioneering research, global outreach, and a commitment to social accountability, environmental impact, and collaboration with partners worldwide.
Industries
Nr. of Employees
small (1-50)
Reven Pharmaceuticals
2921 W. 120th Ave / Suite 220 Westminster, CO 80234
Patents
Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US-11202798-B2
View DetailsCompositions and methods for the prevention and treatment of cardiovascular diseases
US-11110053-B2
View DetailsMethods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US-9867849-B2
View DetailsCompositions and methods for the prevention and treatment of cardiovascular diseases
US-9775798-B2
View Details
Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US-11202798-B2
View DetailsCompositions and methods for the prevention and treatment of cardiovascular diseases
US-11110053-B2
View DetailsMethods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US-9867849-B2
View DetailsCompositions and methods for the prevention and treatment of cardiovascular diseases
US-9775798-B2
View DetailsProducts
Intravenous multimodal therapeutic platform
An intravenous therapeutic formulation designed to provide multimodal cellular support (immune modulation, metabolic support, microenvironment modulation) intended for inflammatory-driven and metabolic dysfunction conditions and adaptable across indications.
Intravenous multimodal therapeutic platform
An intravenous therapeutic formulation designed to provide multimodal cellular support (immune modulation, metabolic support, microenvironment modulation) intended for inflammatory-driven and metabolic dysfunction conditions and adaptable across indications.
Services
Assessment and administration of individual and group expanded access/compassionate use requests including physician-submitted applications and regulatory/ethics coordination.
Operational execution of multi-center Phase 1/2 and Phase 2 clinical studies, including protocol development, site coordination, and partner/CRO management.
Support for regulatory filing preparation and interactions to enable human studies, including IND-level preparations.
Outsourced coordination of analytical chemistry, stability, bioanalytical assays and GLP toxicology testing through third‑party laboratories.
Assessment and administration of individual and group expanded access/compassionate use requests including physician-submitted applications and regulatory/ethics coordination.
Operational execution of multi-center Phase 1/2 and Phase 2 clinical studies, including protocol development, site coordination, and partner/CRO management.
Support for regulatory filing preparation and interactions to enable human studies, including IND-level preparations.
Outsourced coordination of analytical chemistry, stability, bioanalytical assays and GLP toxicology testing through third‑party laboratories.
Expertise Areas
- Clinical trial management
- Expanded access program administration
- Drug formulation and CMC for intravenous therapies
- Preclinical animal model development
Key Technologies
- Intravenous drug formulation
- Multimodal therapeutic platforms
- Preclinical animal disease models (including LPS-GalN model)
- Phase 1/2 randomized double-blind clinical trial design
News & Updates
Reven has filed an appeal related to ongoing legal proceedings and investigations.
Reven has responded to SEC allegations, asserting that there has been no misappropriation or material misstatements, and that the SEC's claims are baseless.
Reven has conducted multiple clinical trials and research studies on RJX, including safety profiles, efficacy, and potential applications in COVID-19, sepsis, and other conditions.
Reven announced the first patient dosed in its Phase 2 clinical trial evaluating RJX for high-risk COVID-19 patients.
Reven has filed an appeal related to ongoing legal proceedings and investigations.
Reven has responded to SEC allegations, asserting that there has been no misappropriation or material misstatements, and that the SEC's claims are baseless.
Reven has conducted multiple clinical trials and research studies on RJX, including safety profiles, efficacy, and potential applications in COVID-19, sepsis, and other conditions.
Reven announced the first patient dosed in its Phase 2 clinical trial evaluating RJX for high-risk COVID-19 patients.